NCT04302441Unknown2 期
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab as the Adjuvant Treatment of HER2 Positive Patients Following Neoadjuvant Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 550
- 试验地点
- 1
- 主要终点
- Disease free survival
研究概览
简要总结
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 70 years old
- •Patients with histologically confirmed unilateral invasive ductal carcinoma(according to WHO histologically type)
- •Tumor clinical staged as IIB-IIIB before neoadjuvant chemotherapy (according to the 7th AJCC edition).
- •After standard treatment (at least 6 cycles) of neoadjuvant chemotherapy (plan formulated by the attending doctor, including anthracycline and paclitaxel drugs combined with trastuzumab), assessed by the surgery, the original site for non - pCR (MP class 1-4) or lymph nodes are still positive for patients.
- •No gross or microscopic tumor residual after resection.
- •Patients with Her2 receptor positive (Specific definition: immunohistochemical detection of Her2 3+ or Her2 2 + but after FISH or CISH tested is positive).
- •No evidence of distant metastasis in the clinical or radiological aspects of preoperative. examination,that is M
- •Patients without peripheral neuropathy or I peripheral neurotoxicity.
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤
- •Patients recovered well after surgery, at least 1 weeks after the operation.
- •Adequate marrow: White blood cells count≥3000/μL,neutrophil count ≥1500/μL, hemoglobin ≥9g/dL and platelet count ≥75000/μL.
- •Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤ 2.5×ULN, and bilirubin ≤ 1.5ULN.
- •Adequate renal function: Serum creatinine ≤ 1.5ULN.
- •Contraception during the treatment of child-bearing women.
- •Adequate cardiac function :Left ventricular ejection fraction (LVEF) > 50%.
- •Patients must be informed of the investigational nature of this study and give written informed consent.
- •Patients without serious heart, lung, liver, kidney and other important organs disease history.
- •Patients have good compliance.
排除标准
- •Patients with bilateral breast cancer or carcinoma in situ(DCIS/LCIS).
- •Metastasis of any part except axillary lymph nodes.
- •Clinical or imaging suspicion of the contralateral breast is malignant but not confirmed, requiring biopsy.
- •There have been malignant tumors (except for basal cell carcinoma and carcinoma in situ of cervix) in the last five years, including breast cancer.
- •Patients have been enrolled in other clinical trials.
- •Patients with severe systemic illnesses and/or uncontrolled infections are unable to join the study.
- •Patients with severe cardio-cerebrovascular disorders (e.g., unstable angina pectoris, chronic heart failure, uncontrollable hypertension >160/100mmgh, myocardial infarction or cerebrovascular accident) in the first 6 months of randomization.
- •Pregnant lactating women (child-bearing women must be negative for pregnancy test within 14 days prior to first delivery, if positive, the pregnancy should be excluded by ultrasound.)
- •Child-bearing women who are unwilling to take effective contraceptive measures in the course of research.
- •Patients with mental illness, cognitive impairment, inability to understand test protocols and side effects, and those who fail to complete the trial programme and follow-up work (a systematic assessment is required before the trial).
- •Persons without personal freedom and independent civil capacity.
研究组 & 干预措施
NXH group
Experimental
Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
干预措施: Vinorelbine (Drug)
NXH group
Experimental
Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).
干预措施: Capecitabine (Drug)
结局指标
主要结局
Disease free survival
时间窗: 3 year
The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer
次要结局
- Overall survival(5=3 year)
- Recurrence free survival(3 year)
- Distant disease free survival(3 year)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast CancerMetastatic Breast CancerNCT00431704National Cancer Institute, Naples39
终止
2 期
Trastuzumab and Vinorelbine in Advanced Breast CancerBreast CancerMetastatic Breast CancerNCT01185509Dana-Farber Cancer Institute31
终止
2 期
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With TrastuzumabBreast CancerNCT00130507Spanish Breast Cancer Research Group14
已完成
1 期
A Phase I/II Study of Vinorelbine plus Trastuzumab in Patients with Advanced/Recurrent Breast Cancer Previously Treated with Anthracyclines and TaxanesBreast cancerJPRN-C000000447Kyushu Breast Cancer Study Group60
已完成
3 期
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast CancerMetastatic Breast CancerNCT00868634iOMEDICO AG600